Oncogene  2001 Jul 19;20(32):4416-8 

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

Sibley K, Stern P, Knowles MA.

ICRF Clinical Centre, St. James's University Hospital, Leeds, LS9 7TF, UK.

Mutations in FGFR3 have been identified in several tumour types including
bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder
carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this
the most frequently mutated putative oncogene identified in bladder cancer to
date. We have now investigated the frequency of FGFR3 mutation in a panel of 125
tumours and 13 cell lines from various other organs. We analysed the mutation
hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation
in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected
in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours,
nor were they found in any of the cell lines included in this study. We conclude
that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical
carcinoma. Several tumour types appear not to possess any mutations in FGFR3,
suggesting that these mutations are important only in the development of certain
types of tumour.

PMID: 11466624 [PubMed - indexed for MEDLINE]